Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression

被引:0
作者
Ansseau, M
Bataille, M
Briole, G
DeNayer, A
Fauchere, PA
Ferrero, F
Mertens, C
Realini, R
Rombaut, P
Vereecken, A
Troisfontaines, B
VanMoffaert, M
机构
[1] CLIN NOTRE DAME, B-4681 HERMALLE SARGENTEA, BELGIUM
[2] CTR INSTRUCT ARMEES VAL DE GRACE, F-75230 PARIS, FRANCE
[3] CLIN ST THERESE, B-6061 Montignies Sur Sambre, BELGIUM
[4] UNIV LAUSANNE, POLICLIN PSYCHIAT B, CH-1005 LAUSANNE, SWITZERLAND
[5] ST VINCENTS CLIN, B-4000 ROCOURT, BELGIUM
[6] AKAD ZIEKENHUIS, PSYCHIAT KLIN, B-9000 GHENT, BELGIUM
[7] PSYCHIAT CTR SLEIDINGE, B-9940 EVERGEM, BELGIUM
[8] PSYCHIAT ZIEKENHUIS SINT JAN, B-9900 EEKLO, BELGIUM
关键词
adjustment disorders; mixed anxiety depressive disorder; tianeptine; mianserin; alprazolam; antidepressant drugs;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A multicentre study compared tianeptine (37 . 5 mg/day), an original psychotropic compound characterized by both antidepressant and anxiolytic potentials, with a reference antidepressant, mianserin (60 mg/day) and a reference anxiolytic, alprazolam (1 . 5 mg/day), in the treatment of 152 patients fulfilling DSM-III-R criteria for adjustment disorder with mixed emotional features (anxiety and depression). The study used a double-blind parallel design over a 6-week period. Clinical assessments included the Clinical Global Impressions (CGI), the Montgomery and Asberg depression rating scale (MADRS), the Hamilton anxiety rating scale, a visual analogue scale, and the somatic scale of the system developed by the Association for the Methodology and Documentation in Psychiatry (AMDP). Results showed very similar improvement in the three treatment groups on all rating instruments. Moreover, the number of patients exhibiting adverse events did not differ among the three groups. Therefore, these results show similar antidepressant and anxiolytic activity for tianeptine, mianserin and alprazolam in patients suffering from adjustment disorder with mixed emotional features. These promising findings should however be confirmed in a placebo-controlled trial.
引用
收藏
页码:293 / 298
页数:6
相关论文
共 25 条
[1]  
[Anonymous], 1992, INT CLASS DIS
[2]  
Ansseau M., 1993, European Psychiatry, V8, p89S
[3]  
BOBON D, 1983, AMDP SYSTEM PHARMACO
[4]   The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder [J].
Bouffard, R ;
Hechtman, L ;
Minde, K ;
Iaboni-Kassab, F .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (08) :546-554
[5]   MIANSERIN - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN DEPRESSIVE-ILLNESS [J].
BROGDEN, RN ;
HEEL, RC ;
SPEIGHT, TM ;
AVERY, GS .
DRUGS, 1978, 16 (04) :273-301
[6]   INFLUENCE OF THE NOVEL ANTIDEPRESSANT TIANEPTINE ON NEUROCHEMICAL, NEUROENDOCRINOLOGICAL, AND BEHAVIORAL-EFFECTS OF STRESS IN RATS [J].
BROQUA, P ;
BAUDRIE, V ;
LAUDE, D ;
CHAOULOFF, F .
BIOLOGICAL PSYCHIATRY, 1992, 31 (04) :391-400
[7]   SYMPTOMATIC VOLUNTEERS IN MULTICENTER DRUG TRIALS [J].
COVI, L ;
LIPMAN, RS ;
MCNAIR, DM ;
CZERLINSKY, T .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY, 1979, 3 (5-6) :521-533
[8]  
CPMP Working Party on Efficacy of Medicinal Products, 1990, PHARMACOL TOXICOL, V67, P361
[9]   THE NOVEL ANTIDEPRESSANT, TIANEPTINE, REDUCES STRESS-EVOKED STIMULATION OF THE HYPOTHALAMO-PITUITARY-ADRENAL AXIS [J].
DELBENDE, C ;
CONTESSE, V ;
MOCAER, E ;
KAMOUN, A ;
VAUDRY, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1991, 202 (03) :391-396
[10]  
Fontanges R., 1993, European Psychiatry, V8, p67S